NASDAQ:EXAS - EXACT Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$68.31 +0.46 (+0.68 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$68.31
Today's Range$66.55 - $68.71
52-Week Range$37.36 - $82.85
Volume1.47 million shs
Average Volume1.26 million shs
Market Capitalization$8.40 billion
P/E Ratio-69.00
Dividend YieldN/A
Beta1.2
EXACT Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. It has an intellectual property, which protects its non invasive, molecular screening technology for the detection of colorectal cancer. The company was founded on February 10, 1995 and is headquartered in Madison, WI.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
Previous Symbol
CUSIP30063P10
Phone608-284-5700

Debt

Debt-to-Equity Ratio0.94
Current Ratio12.08
Quick Ratio11.72

Price-To-Earnings

Trailing P/E Ratio-69.00
Forward P/E Ratio-45.24
P/E GrowthN/A

Sales & Book Value

Annual Sales$265.99 million
Price / Sales31.56
Cash FlowN/A
Price / Cash FlowN/A
Book Value$4.35 per share
Price / Book15.70

Profitability

EPS (Most Recent Fiscal Year)($0.99)
Net Income$-114,390,000.00
Net Margins-35.83%
Return on Equity-20.18%
Return on Assets-11.11%

Miscellaneous

Employees1,268
Outstanding Shares122,900,000
Market Cap$8.40 billion
OptionableOptionable

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) issued its quarterly earnings results on Tuesday, October, 30th. The medical research company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. The medical research company earned $118.29 million during the quarter, compared to analyst estimates of $109.33 million. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. EXACT Sciences's revenue for the quarter was up 63.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.23) earnings per share. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Thursday, February 28th 2019. View Earnings Estimates for EXACT Sciences.

What guidance has EXACT Sciences issued on next quarter's earnings?

EXACT Sciences updated its FY 2018 earnings guidance on Tuesday, October, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $435-440 million, compared to the consensus revenue estimate of $428.75 million.

What price target have analysts set for EXAS?

12 analysts have issued 1 year price targets for EXACT Sciences' stock. Their forecasts range from $65.00 to $100.00. On average, they anticipate EXACT Sciences' stock price to reach $86.0909 in the next twelve months. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

What are Wall Street analysts saying about EXACT Sciences stock?

Here are some recent quotes from research analysts about EXACT Sciences stock:
  • 1. According to Zacks Investment Research, "EXACT Sciences Corporation uses applied genomics to develop effective, patient-friendly screening technologies for use in the detection of cancer. Certain of its technologies have been licensed to Laboratory Corporation of America Holdings for a stool-based DNA screening assay for colorectal cancer in the average-risk population. Colorectal cancer, which is the most deadly cancer among non-smokers, is generally curable if detected early. Despite the availability of colorectal cancer screening and diagnostic tests for more than twenty years, the rate of early detection of colorectal cancer remains low, and deaths from colorectal cancer remain high. EXACT Sciences believes its genomics-based technologies would help to enable detection of colorectal cancer so that more people can be effectively treated. " (10/30/2018)
  • 2. BTIG Research analysts commented, "5 th , data on Exact Sciences’ second case control study for its liver biomarker is scheduled to be presented at the Digestive Disease Week (DDW) conference. Recall that the biomarkers are being co-developed with the Mayo Clinic. The abstract is available on DDW’s website and preliminary details show encouraging 95% sensitivity across all stages (93% specificity in healthy controls, 86% specificity in cirrhotic controls). A liver screening test is one of a number of platforms in EXAS’ cancer pipeline and given the improving traction here, may be the second real shot on the goal, though years away. While we don’t view this as a material stock-moving event, pipeline advancement is supportive of our positive thesis on the name. We reiterate our Buy rating and $70 PT." (6/5/2018)

Has EXACT Sciences been receiving favorable news coverage?

News articles about EXAS stock have trended somewhat positive on Sunday, InfoTrie reports. The research group identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Who are some of EXACT Sciences' key competitors?

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Kevin T. Conroy, Chairman, President & Chief Executive Officer
  • Jeffrey T. Elliott, Chief Financial Officer
  • Barry M. Berger, Co-Chief Medical Officer & Head-Medical Affairs
  • Graham Peter Lidgard, Chief Science Officer, SVP-Research & Development
  • Gary Frings, Chief Information Officer

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.54%), Vanguard Group Inc (8.54%), OppenheimerFunds Inc. (3.68%), William Blair Investment Management LLC (1.90%), Alliancebernstein L.P. (1.85%) and Gilder Gagnon Howe & Co. LLC (1.59%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which institutional investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, OppenheimerFunds Inc., Macquarie Group Ltd., Victory Capital Management Inc., Alliancebernstein L.P., Wasatch Advisors Inc., Zweig DiMenna Associates LLC and Artemis Investment Management LLP. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Michael S Wyzga and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

Which institutional investors are buying EXACT Sciences stock?

EXAS stock was acquired by a variety of institutional investors in the last quarter, including William Blair Investment Management LLC, First Trust Advisors LP, Frontier Capital Management Co. LLC, Eagle Asset Management Inc., Baillie Gifford & Co., Carillon Tower Advisers Inc., MARSHALL WACE ASIA Ltd and Vanguard Group Inc. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $68.31.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $8.40 billion and generates $265.99 million in revenue each year. The medical research company earns $-114,390,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. EXACT Sciences employs 1,268 workers across the globe.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is http://www.exactsciences.com.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  701 (Vote Outperform)
Underperform Votes:  410 (Vote Underperform)
Total Votes:  1,111
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel